LLY - Eli Lilly's Legal Battle Against Fake Compounded Tirzepatide Products: Bacteria Impurities Detected | Benzinga
Eli Lilly And Co (NYSE:LLY) revealed on Thursday that it has identified bacteria and elevated impurity levels in products falsely claiming to be compounded versions of tirzepatide, the active ingredient in its widely-used diabetes medication Mounjaro and the weight loss treatment Zepbound.
The U.S. pharmaceutical giant has taken legal action against numerous medical spas, weight-loss clinics, and compounding pharmacies to halt the sale of these fraudulent products.
Related Content: Eli Lilly’s Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets.
Compounded drugs, custom-made medicines with the same ingredients as branded versions, offer a potentially cheaper alternative but are ...